Form 4: Akebia CEO Butler Reports RSU, PSU Vesting & Tax-Related Sales
Insider Transaction Report
Akebia Therapeutics CEO John P. Butler reported the vesting of restricted and performance stock units and subsequent tax-related sales of common stock.
Summary
- John P. Butler, CEO and President of Akebia Therapeutics, Inc., reported multiple transactions on February 2, 2026.
- He acquired 175,250 shares of common stock at $1.41 per share due to the vesting of performance-based restricted stock units (PSUs).
- This PSU vesting occurred because the Compensation Committee certified in July 2025 that the company's stock price met the "Stock Price Hurdle 1 Performance Condition" of $3.50 over a 30-day trading period.
- He disposed of a total of 341,305 shares of common stock at $1.39 per share through multiple sales.
- These sales were primarily automatic transactions by the Issuer to cover tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs) granted in 2023, 2024, and 2025, and performance stock units granted in 2025.
- All sales were conducted under a Rule 10b5-1 trading plan adopted on September 8, 2025.
- Following these transactions, Butler directly beneficially owns 3,297,794 shares of common stock and indirectly owns 159,928 shares through the Dorothy Butler Revocable Trust.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as moderately positive. While there are sales, they are for tax purposes and pre-scheduled. The vesting of PSUs due to a stock price hurdle being met is a positive indicator of past stock performance and achievement of compensation targets.
Positives
- Vesting of 175,250 performance-based restricted stock units (PSUs) indicates the achievement of a stock price hurdle, specifically the average closing price of Akebia's common stock equaling or exceeding $3.50 over a 30-day trading period.
- The achievement of the stock price hurdle in July 2025 suggests positive stock performance leading up to that date.
Negatives
- Sales of 341,305 shares of common stock, although primarily for tax withholding, reduce the direct beneficial ownership of the CEO.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that insider transactions, particularly those related to pre-scheduled vesting and tax obligations under a Rule 10b5-1 plan, are common occurrences in the biotechnology and pharmaceutical sectors. While these transactions provide transparency into executive compensation and ownership, they typically do not reflect a discretionary change in an insider's view of the company's immediate prospects, unlike open market purchases or sales.
Related Party Transactions
- The reported transactions are between John P. Butler, a director and officer, and Akebia Therapeutics, Inc., which are inherently related party transactions concerning executive compensation and share ownership.
Stakeholder Impact
- Shareholders: Provides transparency into executive compensation and ownership changes. The achievement of a stock price hurdle for PSU vesting could be seen positively as it indicates past stock performance.
- Employees: Reflects the structure of executive compensation, which may influence broader employee incentive programs.
Next Steps
- Future vesting of remaining restricted stock units and performance stock units as per their respective schedules.
Key Dates
| Date | Description |
|---|---|
| 2007-11-20 | Establishment of Dorothy Butler Revocable Trust. |
| 2023-01-31 | Grant date for restricted stock units, one-third of which vested and settled on February 2, 2026. |
| 2024-01-31 | Grant date for restricted stock units, one-third of which vested and settled on February 2, 2026. |
| 2025-01-31 | Grant date for restricted stock units, one-third of which vested and settled on February 2, 2026. |
| 2025-01-31 | Grant date for performance stock units, one-half of which vested and settled on February 2, 2026. |
| 2025-02 | Reporting Person was granted performance-based restricted stock units (PSUs) pursuant to the Issuer's 2023 Stock Incentive Plan. |
| 2025-07 | Compensation Committee certified that the Stock Price Hurdle 1 Performance Condition was met. |
| 2025-09-08 | Date Rule 10b5-1 trading plan was adopted by the reporting person. |
| 2026-02-02 | Date of earliest transaction reported, including sales for tax withholding and PSU vesting. |
| 2026-02-04 | Signature date of the reporting person's attorney-in-fact. |
Keywords
Akebia Therapeutics, AKBA, John P. Butler, Form 4, Insider Trading, Stock Units, Restricted Stock Units, Performance Stock Units, RSU Vesting, PSU Vesting, Tax Withholding, Rule 10b5-1 Plan, Beneficial Ownership, CEO Transactions
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.